Rationale and design of the PRognostic Importance of MIcrovascular Dysfunction in asymptomatic patients with Aortic Stenosis (PRIMID-AS): a multicentre observational study with blinded investigations
View/ Open
Author
Singh, Anvesha
Ford, Ian
Greenwood, John P
Khan, Jamal N
Uddin, Akhlaque
Berry, Colin
Neubauer, Stefan
Prendergast, Bernard
Williams, Bryan
Samani, Nilesh J
McCann, Gerry P
Note: Order does not necessarily reflect citation order of authors.
Published Version
https://doi.org/10.1136/bmjopen-2013-004348Metadata
Show full item recordCitation
Singh, A., I. Ford, J. P. Greenwood, J. N. Khan, A. Uddin, C. Berry, S. Neubauer, et al. 2013. “Rationale and design of the PRognostic Importance of MIcrovascular Dysfunction in asymptomatic patients with Aortic Stenosis (PRIMID-AS): a multicentre observational study with blinded investigations.” BMJ Open 3 (12): e004348. doi:10.1136/bmjopen-2013-004348. http://dx.doi.org/10.1136/bmjopen-2013-004348.Abstract
Introduction: Aortic stenosis (AS) is the commonest valve disorder in the developed world requiring surgery. Surgery in patients with severe asymptomatic AS remains controversial. Exercise testing can identify asymptomatic patients at increased risk of death and symptom development, but with limited specificity, especially in older adults. Cardiac MRI (CMR), including myocardial perfusion reserve (MPR) may be a novel imaging biomarker in AS. Aims (1) To improve risk stratification in asymptomatic patients with AS and (2) to determine whether MPR is a better predictor of outcome than exercise testing and brain natriuretic peptide (BNP). Method/design Multicentre, prospective observational study in the UK, comparing MPR with exercise testing and BNP (with blinded CMR analysis) for predicting outcome. Population 170 asymptomatic patients with moderate-to-severe AS, who would be considered for aortic valve replacement (AVR). Primary outcome Composite of: typical symptoms necessitating referral for AVR and major adverse cardiovascular events. Follow-up: 12–30 months (minimum 12 months). Primary hypothesis MPR will be a better predictor of outcome than exercise testing and BNP. Ethics/dissemination The study has full ethical approval and is actively recruiting patients. Data collection will be completed in November 2014 and the study results will be submitted for publication within 6 months of completion. ClinicalTrials.gov identifier NCT01658345.Other Sources
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3884636/pdf/Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAACitable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:11879581
Collections
- HMS Scholarly Articles [17922]
Contact administrator regarding this item (to report mistakes or request changes)